Skip to main content

Relugolix (Orgovyx®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA995: Relugolix for treating hormone-sensitive prostate cancer

Medicine details

Medicine name Relugolix (Orgovyx®)
Formulation 120 mg film-coated tablets
Reference number 3502
Indication

For the treatment of adult patients with advanced hormone-sensitive prostate cancer

Company Accord-UK Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
Date of issue 01/07/2024
NICE guidance

TA995: Relugolix for treating hormone-sensitive prostate cancer

Follow AWTTC: